Delineation of molecular pathway activities of the chronic antidepressant treatment response suggests important roles for glutamatergic and ubiquitin-proteasome systems

Translational Psychiatry

Volumn 7, Issue 4, 2017, Pages

  Park, D I ^a   Dournes, C ^a   Sillaber, I ^b   Ising, M ^a   Asara, J M ^c,d   Webhofer, C ^a   Filiou, M D ^a   Muller M B ^e   Turck, C W ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b Phenoquest AG   (Germany)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CARBOXY TERMINAL PDZ LIGAND OF NEURONAL NITRIC OXIDE SYNTHASE; CITRULLINE; GLUTAMATE AMMONIA LIGASE; GLUTAMATE DEHYDROGENASE; GLUTAMATE DEHYDROGENASE 1; GLUTAMIC ACID; GLYCOGEN SYNTHASE KINASE 3BETA; GUANYLATE CYCLASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEURONAL NITRIC OXIDE SYNTHASE; NORADRENALIN UPTAKE INHIBITOR; OXYGENASE; PAROXETINE; PHOSPHO CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; PHOSPHO EXTRACELLULAR SIGNAL REGULATED KINASE; PHOSPHOPROTEIN; POSTSYNAPTIC DENSITY PROTEIN 95; PROTEASOME; PROTEASOME SUBUNIT ALPHA TYPE 2; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SOLUBLE GUANYLATE CYCLASE BETA 1; SYNAPSIN; SYNAPTOJANIN; SYNAPTOJANIN 1; TRICYCLIC ANTIDEPRESSANT AGENT; UBIQUITIN; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; FORCED SWIM TEST; GLUTAMATERGIC SYSTEM; HIPPOCAMPUS; HUMAN; HUMAN CELL; IMMOBILITY; LONG TERM CARE; MAJOR DEPRESSION; MALE; MENTAL PATIENT; METABOLOMICS; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PREFRONTAL CORTEX; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; PROTEOMICS; PSYCHOPHARMACOTHERAPY; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; UBIQUITIN PROTEASOME SYSTEM; UBIQUITINATION; UPREGULATION; ANIMAL; DBA MOUSE; DRUG EFFECTS; METABOLISM; MONONUCLEAR CELL; PHYSIOLOGY; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; GLUTAMIC ACID; HIPPOCAMPUS; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; METABOLOMICS; MICE; MICE, INBRED DBA; NITRIC OXIDE SYNTHASE TYPE I; PAROXETINE; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOMICS; RECEPTORS, N-METHYL-D-ASPARTATE; SWIMMING; UBIQUITIN;

EID: 85016969869     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2017.39     Document Type: Article

References (98)

1. Al-Harbi KS. Treatment-resistant depression: Therapeutic trends, challenges, and future directions. Patient Prefer Adherence 2012; 6: 369-388.
2. Thomas L, Kessler D, Campbell J, Morrison J, Peters TJ, Williams C, et al. Prevalence of treatment-resistant depression in primary care: Cross-sectional data. Br J Gen Pract 2013; 63: E852-e858.
3. Berlim MT, Turecki G. Definition, assessment, and staging of treatment-resistant refractory major depression: A review of current concepts and methods. Can J Psychiatry 2007; 52: 46-54.
4. Huezo-Diaz P, Uher R, Smith R, Rietschel M, Henigsberg N, Marusic A, et al. Moderation of antidepressant response by the serotonin transporter gene. Br J Psychiatry 2009;195: 30-38.
5. Samuels BA, Anacker C, Hu A, Levinstein MR, Pickenhagen A, Tsetsenis T, et al. 5-HT1A receptors on mature dentate gyrus granule cells are critical for the antidepressant response. Nat Neurosci 2015; 18: 1606-1616.
6. Binder EB, Künzel HE, Nickel T, Kern N, Pfennig A, Majer M, et al. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients. Psychoneuroendocrinology 2008; 34: 99-109.
7. Chen Z-Y, Jing D, Bath KG, Ieraci A, Khan T, Siao C-J, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006;314: 140-143.
8. Kocabas NA, Antonijevic I, Faghel C, Forray C, Kasper S, Lecrubier Y, et al. Brainderived neurotrophic factor gene polymorphisms: Influence on treatment response phenotypes of major depressive disorder. Int Clin Psychopharmacol 2011; 26: 1-10.
9. Martinez JM, Garakani A, Yehuda R, Gorman JM. Proinflammatory and "resiliency" proteins in the CSF of patients with major depression. Depress Anxiety 2012; 29: 32-38.
10. Fitzgerald P, O'Brien SM, Scully P, Rijkers K, Scott LV, Dinan TG. Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression. Psychol Med 2006; 36: 37-43.
11. Sluzewska A, Sobieska M, Rybakowski JK. Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression. Neuropsychobiology 1997; 35: 123-127.
12. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 2000; 22: 370-379.
13. Drevets WC, Zarate CA, Furey ML. Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: A review. Biol Psychiatry 2013; 73: 1156-1163.
14. Murrough JW, Iosifescu DV, Chang LC, Jurdi Al RK, Green CE, Perez AM, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: A two-site randomized controlled trial. Am J Psychiatry 2013; 170: 1134-1142.
15. Duman RS, Li N. A neurotrophic hypothesis of depression: Role of synaptogenesis in the actions of NMDA receptor antagonists. Philos Trans R Soc Lond B Biol Sci 2012; 367: 2475-2484.
16. Weckmann K, Labermaier C, Asara JM, Müller MB, Turck CW. Time-dependent metabolomic profiling of Ketamine drug action reveals hippocampal pathway alterations and biomarker candidates. Transl Psychiatry 2014; 4: E481.
17. Webhofer C, Gormanns P, Reckow S, Lebar M, Maccarrone G, Ludwig T, et al. Proteomic and metabolomic profiling reveals time-dependent changes in hippocampal metabolism upon paroxetine treatment and biomarker candidates. J Psychiatr Res 2013; 47: 289-298.
18. Sillaber I, Panhuysen M, Henniger MSH, Ohl F, Kühne C, Pütz B, et al. Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology (Berl) 2008; 200: 557-572.
19. Droy-Dupré L, Bossard C, Volteau C, Bezieau S, Laboisse CL, Mosnier J-F. Hierarchical clustering identifies a subgroup of colonic adenocarcinomas expressing crypt-like differentiation markers, associated with MSS status and better prognosis. Virchows Arch 2015; 466: 383-391.
20. Muehlmann AM, Bliznyuk N, Duerr I, Lewis MH. Repetitive motor behavior: Further characterization of development and temporal dynamics. Dev Psychobiol 2015; 57: 201-211.
21. Webhofer C, Gormanns P, Tolstikov V, Zieglgänsberger W, Sillaber I, Holsboer F, et al. Metabolite profiling of antidepressant drug action reveals novel drug targets beyond monoamine elevation. Transl Psychiatry 2011; 1: E58.
22. Doucet MV, Levine H, Dev KK, Harkin A. Small-molecule inhibitors at the PSD-95/nNOS interface have antidepressant-like properties in mice. Neuropsychopharmacology 2013; 38: 1575-1584.
23. Malkesman O, Scattoni ML, Paredes D, Tragon T, Pearson B, Shaltiel G, et al. The female urine sniffing test: A novel approach for assessing reward-seeking behavior in rodents. Biol Psychiatry 2010; 67: 864-871.
24. Altamura CA, Mauri MC, Ferrara A, Moro AR, D'Andrea G, Zamberlan F. Plasma and platelet excitatory amino acids in psychiatric disorders. Am J Psychiatry 1993; 150: 1731-1733.
25. Kim JS, Schmid-Burgk W, Claus D, Kornhuber HH. Increased serum glutamate in depressed patients. Arch Psychiatr Nervenkr (1970) 1982; 232: 299-304.
26. Levine J, Panchalingam K, Rapoport A, Gershon S, McClure RJ, Pettegrew JW. Increased cerebrospinal fluid glutamine levels in depressed patients. Biol Psychiatry 2000; 47: 586-593.
27. Mauri MC, Ferrara A, Boscati L, Bravin S, Zamberlan F, Alecci M, et al. Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment. Neuropsychobiology 1998; 37: 124-129.
28. Mitani H, Shirayama Y, Yamada T, Maeda K, Ashby CR, Kawahara R. Correlation between plasma levels of glutamate, alanine and serine with severity of depression. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1155-1158.
29. Fabbri C, Drago A, Serretti A. Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR,D. Eur Neuropsychopharmacol 2013; 23: 612-621.
30. Bonanno G, Giambelli R, Raiteri L. Chronic antidepressants reduce depolarizationevoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus. J Neurosci 2005; 25: 3270-3279.
31. Musazzi L, Milanese M, Farisello P, Zappettini S, Tardito D, Barbiero VS, et al. Acute stress increases depolarization-evoked glutamate release in the rat prefrontal/frontal cortex: The dampening action of antidepressants. PLoS ONE 2010; 5: E8566.
32. Calabrese F, Guidotti G, Molteni R, Racagni G, Mancini M, Riva MA. Stress-induced changes of hippocampal NMDA receptors: Modulation by duloxetine treatment. PLoS ONE 2012; 7: E37916.
33. Pittaluga A, Raiteri L, Longordo F, Luccini E, Barbiero VS, Racagni G, et al. Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus. Neuropharmacology 2007; 53: 27-36.
34. Barbon A, Popoli M, La Via L, Moraschi S, Vallini I, Tardito D, et al. Regulation of editing and expression of glutamate alpha-amino-propionic-acid (AMPA)/kainate receptors by antidepressant drugs. Biol Psychiatry 2006; 59: 713-720.
35. Lotrich FE, Pollock BG. Candidate genes for antidepressant response to selective serotonin reuptake inhibitors. Neuropsychiatr Dis Treat 2005; 1: 17-35.
36. Bao X, Pal R, Hascup KN, Wang Y, Wang W-T, Xu W, et al. Transgenic expression of Glud1 (glutamate dehydrogenase 1) in neurons: In vivo model of enhanced glutamate release, altered synaptic plasticity, and selective neuronal vulnerability. J Neurosci 2009; 29: 13929-13944.
37. Michaelis EK, Wang X, Pal R, Bao X, Hascup KN, Wang Y, et al. Neuronal Glud1 (glutamate dehydrogenase 1) over-expressing mice: Increased glutamate formation and synaptic release, loss of synaptic activity, and adaptive changes in genomic expression. Neurochem Int 2011; 59: 473-481.
38. Tsai S-J, Liou Y-J, Hong C-J, YW-Y Yu, Chen T-J. Glycogen synthase kinase-3beta gene is associated with antidepressant treatment response in Chinese major depressive disorder. Pharmacogenomics J 2008; 8: 384-390.
39. Joaquim HPG, Talib LL, Forlenza OV, Diniz BS, Gattaz WF. Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression. J Psychiatr Res 2012; 46: 1053-1058.
40. Qi X, Lin W, Li J, Li H, Wang W, Wang D, et al. Fluoxetine increases the activity of the ERK-CREB signal system and alleviates the depressive-like behavior in rats exposed to chronic forced swim stress. Neurobiol Dis 2008; 31: 278-285.
41. Gourley S, Wu F, Kiraly D, Ploski J, Kedves A. Regionally specific regulation of ERK MAP kinase in a model of antidepressant-sensitive chronic depression. Biol Psychiatry 2008; 63: 353-359.
42. Dwivedi Y, Rizavi HS, Roberts RC, Conley RC, Tamminga CA, Pandey GN. Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. J Neurochem 2001; 77: 916-928.
43. Mani M, Lee SY, Lucast L, Cremona O, Di Paolo G, De Camilli P, et al. The dual phosphatase activity of synaptojanin1 is required for both efficient synaptic vesicle endocytosis and reavailability at nerve terminals. Neuron 2007; 56: 1004-1018.
44. Lüthi A, Di Paolo G, Cremona O, Daniell L, De Camilli P, McCormick DA. Synaptojanin 1 contributes to maintaining the stability of GABAergic transmission in primary cultures of cortical neurons. J Neurosci 2001; 21: 9101-9111.
45. Wong M-L, O'Kirwan F, Hannestad JP, Irizarry KJL, Elashoff D, Licinio J. St John's wort and imipramine-induced gene expression profiles identify cellular functions relevant to antidepressant action and novel pharmacogenetic candidates for the phenotype of antidepressant treatment response. Mol Psychiatry 2004; 9: 237-251.
46. Ghasemi M, Sadeghipour H, Mosleh A, Sadeghipour HR, Mani AR, Dehpour AR. Nitric oxide involvement in the antidepressant-like effects of acute lithium administration in the mouse forced swimming test. Eur Neuropsychopharmacol 2008; 18: 323-332.
47. Jesse C, Bortolatto C, Savegnago L. Involvement of l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of tramadol in the rat forced swimming test. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1838-1843.
48. Dhir A, Kulkarni S. Involvement of nitric oxide (NO) signaling pathway in the antidepressant action of bupropion, a dopamine reuptake inhibitor. Eur J Pharmacol 2007; 568: 177-185.
49. Wegener G, Volke V, Harvey B, Rosenberg R. Local, but not systemic, administration of serotonergic antidepressants decreases hippocampal nitric oxide synthase activity. Brain Res 2003; 959: 128-134.
50. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor. Psychopharmacol Bull 1996; 32: 653-658.
51. Hiroaki-Sato VA, Sales AJ, Biojone C, Joca SRL. Hippocampal nNOS inhibition induces an antidepressant-like effect: Involvement of 5HT1A receptors. Behav Pharmacol 2014; 25: 187-196.
52. Joca SRL, Guimarães FS. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology (Berl) 2006; 185: 298-305.
53. Tomaz VS, Cordeiro RC, Costa AMN, de Lucena DF, Nobre Júnior HV, de Sousa FCF, et al. Antidepressant-like effect of nitric oxide synthase inhibitors and sildenafil against lipopolysaccharide-induced depressive-like behavior in mice. Neuroscience 2014; 268: 236-246.
54. Zhou Q-G, Hu Y, Hua Y, Hu M, Luo C-X, Han X, et al. Neuronal nitric oxide synthase contributes to chronic stress-induced depression by suppressing hippocampal neurogenesis. J Neurochem 2007; 103: 1843-1854.
55. Zhou Q-G, Zhu L-J, Chen C, Wu H-Y, Luo C-X, Chang L, et al. Hippocampal neuronal nitric oxide synthase mediates the stress-related depressive behaviors of glucocorticoids by downregulating glucocorticoid receptor. J Neurosci 2011; 31: 7579-7590.
56. Oliveira RMW, Guimarães FS, Deakin JFW. Expression of neuronal nitric oxide synthase in the hippocampal formation in affective disorders. Braz J Med Biol Res 2008; 41: 333-341.
57. Chrapko W, Jurasz P, Radomski MW, Archer SL, Newman SC, Baker G, et al. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology 2006; 31: 1286-1293.
58. Doucet MV, Harkin A, Dev KK. The PSD-95/nNOS complex: New drugs for depression. Pharmacol Ther 2012; 133: 218-229.
59. Fedele E, Marchi M, Raiteri M. In vivo NO/cGMP signalling in the hippocampus. Neurochem Res 2001; 26: 1069-1078.
60. Bredt DS, Snyder SH. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci USA 1989; 86: 9030-9033.
61. Sharma NM, Zheng H, Mehta PP, Li Y-F, Patel KP. Decreased nNOS in the PVN leads to increased sympathoexcitation in chronic heart failure: Role for CAPON and Ang II. Cardiovasc Res 2011; 92: 348-357.
62. Jaffrey SR, Snowman AM, Eliasson MJ, Cohen NA, Snyder SH. CAPON: A protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95. Neuron 1998; 20: 115-124.
63. Hofmann F, Feil R, Kleppisch T, Schlossmann J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev 2006; 86: 1-23.
64. Francis SH, Busch JL, Corbin JD, Sibley D. cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol Rev 2010; 62: 525-563.
65. Popescu G, Murthy S, Borschel W. Allosteric inhibitors of NMDA receptor functions. Pharmaceuticals 2010; 3: 3240-3257.
66. Westergaard N, Banke T, Wahl P, Sonnewald U, Schousboe A. Citrate modulates the regulation by Zn2+ of N-methyl-D-aspartate receptor-mediated channel current and neurotransmitter release. Proc Natl Acad Sci USA 1995; 92: 3367-3370.
67. Chueh SH. S-Nitrosoglutathione and glutathione act as NMDA receptor agonists in cultured hippocampal neurons1. Acta Pharmacol Sin 2006; 27: 853-860.
68. Rosa JM, Dafre AL, Rodrigues ALS. Antidepressant-like responses in the forced swimming test elicited by glutathione and redox modulation. Behav Brain Res 2013; 253: 165-172.
69. Zhang H, Hyrc K, Thio L. The glycine transport inhibitor sarcosine is an NMDA receptor co?agonist that differs from glycine. J Physiol 2009; 587(Pt 13): 3207-3220.
70. Huang C-C, Wei I-H, Huang C-L, Chen K-T, Tsai M-H, Tsai P, et al. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry 2013; 74: 734-741.
71. Panatier A, Theodosis DT, Mothet J-P, Touquet B, Pollegioni L, Poulain DA, et al. Glia-derived D-serine controls NMDA receptor activity and synaptic memory. Cell 2006; 125: 775-784.
72. Mothet JP, Parent AT, Wolosker H, Brady RO, Linden DJ, Ferris CD, et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 2000; 97: 4926-4931.
73. Suárez LM, Solís JM. Taurine potentiates presynaptic NMDA receptors in hippocampal Schaffer collateral axons. Eur J Neurosci 2006; 24: 405-418.
74. Maes M, Verkerk R, Vandoolaeghe E, Lin A, Scharpé S. Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: Modulation by treatment with antidepressants and prediction of clinical responsivity. Acta Psychiatr Scand 1998; 97: 302-308.
75. Toyoda A, Iio W. Antidepressant-like effect of chronic taurine administration and its hippocampal signal transduction in rats. Adv Exp Med Biol 2013; 775: 29-43.
76. Fazio F, Lionetto L, Curto M, Iacovelli L, Cavallari M, Zappulla C, et al. Xanthurenic acid activates mGlu2/3 metabotropic glutamate receptors and is a potential trait marker for schizophrenia. Sci Rep 2015; 5: 17799.
77. Cebers G, Cebere A, Wägner A, Liljequist S. Prolonged inhibition of glutamate reuptake down-regulates NMDA receptor functions in cultured cerebellar granule cells. J Neurochem 1999; 72: 2181-2190.
78. Cebers G, Cebere A, Kovács AD, Högberg H, Moreira T, Liljequist S. Increased ambient glutamate concentration alters the expression of NMDA receptor subunits in cerebellar granule neurons. Neurochem Int 2001; 39: 151-160.
79. Gragnoli C. Proteasome modulator 9 gene SNPs, responsible for anti-depressant response, are in linkage with generalized anxiety disorder. J Cell Physiol 2014; 229: 1157-1159.
80. Wong M-L, Dong C, Maestre-Mesa J, Licinio J. Polymorphisms in inflammationrelated genes are associated with susceptibility to major depression and antidepressant response. Mol Psychiatry 2008; 13: 800-812.
81. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitinproteasome pathway in normal and disease states. J Am Soc Nephrol 2006; 17: 1807-1819.
82. Park S, Li X, Kim HM, Singh CR, Tian G, Hoyt MA, et al. Reconfiguration of the proteasome during chaperone-mediated assembly. Nature 2013; 497: 512-516.
83. Tai H-C, Schuman EM. Ubiquitin, the proteasome and protein degradation in neuronal function and dysfunction. Nat Rev Neurosci 2008; 9: 826-838.
84. Svenningsson P, Berg L, Matthews D, Ionescu DF, Richards EM, Niciu MJ, et al. Preliminary evidence that early reduction in p11 levels in natural killer cells and monocytes predicts the likelihood of antidepressant response to chronic citalopram. Mol Psychiatry 2014; 19: 962-964.
85. Elfving B, Plougmann PH, Müller HK, Mathé AA, Rosenberg R, Wegener G. Inverse correlation of brain and blood BDNF levels in a genetic rat model of depression. Int J Neuropsychopharmacol 2010; 13: 563-572.
86. Ryan MM, Lockstone HE, Huffaker SJ, Wayland MT, Webster MJ, Bahn S. Gene expression analysis of bipolar disorder reveals downregulation of the ubiquitin cycle and alterations in synaptic genes. Mol Psychiatry 2006; 11: 965-978.
87. Karssen AM, Her S, Li JZ, Patel PD, Meng F, Bunney WE, et al. Stress-induced changes in primate prefrontal profiles of gene expression. Mol Psychiatry 2007; 12: 1089-1102.
88. Tsai N-P. Ubiquitin proteasome system-mediated degradation of synaptic proteins: An update from the postsynaptic side. Biochim Biophys Acta 2014; 1843: 2838-2842.
89. Kato A, Rouach N, Nicoll RA, Bredt DS. Activity-dependent NMDA receptor degradation mediated by retrotranslocation and ubiquitination. Proc Natl Acad Sci USA 2005; 102: 5600-5605.
90. Tai H-C, Besche H, Goldberg AL, Schuman EM. Characterization of the brain 26S proteasome and its interacting proteins. Front Mol Neurosci 2010; 3: 12.
91. Hipp MS, Kalveram B, Raasi S, Groettrup M, Schmidtke G. FAT10, a ubiquitinindependent signal for proteasomal degradation. Mol Cell Biol 2005; 25: 3483-3491.
92. Schmidtke G, Aichem A, Groettrup M. FAT10ylation as a signal for proteasomal degradation. Biochim Biophys Acta 2014; 1843: 97-102.
93. Enchev RI, Schulman BA, Peter M. Protein neddylation: Beyond cullin-RING ligases. Nat Rev Mol Cell Biol 2015; 16: 30-44.
94. Miteva M, Keusekotten K, Hofmann K, Praefcke GJK, Dohmen RJ. Sumoylation as a signal for polyubiquitylation and proteasomal degradation. Subcell Biochem 2010; 54: 195-214.
95. Gassen NC, Hartmann J, Schmidt MV, Rein T. FKBP5/FKBP51 enhances autophagy to synergize with antidepressant action. Autophagy 2015; 11: 578-580.
96. Gassen NC, Hartmann J, Zschocke J, Stepan J, Hafner K, Zellner A, et al. Association of FKBP51 with priming of autophagy pathways and mediation of antidepressant treatment response: Evidence in cells, mice, and humans. PLoS Med 2014; 11: E1001755.
97. Bartolomucci A, Palanza P, Sacerdote P, Ceresini G, Chirieleison A, Panerai AE, et al. Individual housing induces altered immuno-endocrine responses to psychological stress in male mice. Psychoneuroendocrinology 2003; 28: 540-558.
98. Hilakivi LA, Ota M, Lister RG. Effect of isolation on brain monoamines and the behavior of mice in tests of exploration, locomotion, anxiety and behavioral 'despair'. Pharmacol Biochem Behav 1989; 33: 371-374